Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Lucid Diagnostics 2018 Equity Plan [Member] Preferred Stock [Member]	Lucid Diagnostics 2018 Equity Plan [Member] Common Stock [Member]	Lucid Diagnostics 2018 Equity Plan [Member] Additional Paid-in Capital [Member]	Lucid Diagnostics 2018 Equity Plan [Member] Retained Earnings [Member]	Lucid Diagnostics 2018 Equity Plan [Member]	PAVmed 2014 Equity Plan [Member] Preferred Stock [Member]	PAVmed 2014 Equity Plan [Member] Common Stock [Member]	PAVmed 2014 Equity Plan [Member] Additional Paid-in Capital [Member]	PAVmed 2014 Equity Plan [Member] Retained Earnings [Member]	PAVmed 2014 Equity Plan [Member]	Conversion of Senior Secured Convertible Notes into Common Stock [Member] Preferred Stock [Member]	Conversion of Senior Secured Convertible Notes into Common Stock [Member] Common Stock [Member]	Conversion of Senior Secured Convertible Notes into Common Stock [Member] Additional Paid-in Capital [Member]	Conversion of Senior Secured Convertible Notes into Common Stock [Member] Retained Earnings [Member]	Conversion of Senior Secured Convertible Notes into Common Stock [Member]	Series A-1 Preferred Stock [Member] Preferred Stock [Member]	Series A-1 Preferred Stock [Member] Common Stock [Member]	Series A-1 Preferred Stock [Member] Additional Paid-in Capital [Member]	Series A-1 Preferred Stock [Member] Retained Earnings [Member]	Series A-1 Preferred Stock [Member]	Series B and B-1 Preferred Stock [Member] Preferred Stock [Member]	Series B and B-1 Preferred Stock [Member] Common Stock [Member]	Series B and B-1 Preferred Stock [Member] Additional Paid-in Capital [Member]	Series B and B-1 Preferred Stock [Member] Retained Earnings [Member]	Series B and B-1 Preferred Stock [Member]	Conversion of Series A and A-1 Preferred into Series B and B-1 Preferred Stock [Member] Preferred Stock [Member]	Conversion of Series A and A-1 Preferred into Series B and B-1 Preferred Stock [Member] Common Stock [Member]	Conversion of Series A and A-1 Preferred into Series B and B-1 Preferred Stock [Member] Additional Paid-in Capital [Member]	Conversion of Series A and A-1 Preferred into Series B and B-1 Preferred Stock [Member] Retained Earnings [Member]	Conversion of Series A and A-1 Preferred into Series B and B-1 Preferred Stock [Member]	Conversion of Preferred Stock into Common Stock [Member] Preferred Stock [Member]	Conversion of Preferred Stock into Common Stock [Member] Common Stock [Member]	Conversion of Preferred Stock into Common Stock [Member] Additional Paid-in Capital [Member]	Conversion of Preferred Stock into Common Stock [Member] Retained Earnings [Member]	Conversion of Preferred Stock into Common Stock [Member]	PAVmed [Member] Preferred Stock [Member]	PAVmed [Member] Common Stock [Member]	PAVmed [Member] Additional Paid-in Capital [Member]	PAVmed [Member] Retained Earnings [Member]	PAVmed [Member]	At-the-market Offering [Member] Preferred Stock [Member]	At-the-market Offering [Member] Common Stock [Member]	At-the-market Offering [Member] Additional Paid-in Capital [Member]	At-the-market Offering [Member] Retained Earnings [Member]	At-the-market Offering [Member]	Registered Direct Offering [Member] Preferred Stock [Member]	Registered Direct Offering [Member] Common Stock [Member]	Registered Direct Offering [Member] Additional Paid-in Capital [Member]	Registered Direct Offering [Member] Retained Earnings [Member]	Registered Direct Offering [Member]	Confidentially Marketed Public Offering [Member] Preferred Stock [Member]	Confidentially Marketed Public Offering [Member] Common Stock [Member]	Confidentially Marketed Public Offering [Member] Additional Paid-in Capital [Member]	Confidentially Marketed Public Offering [Member] Retained Earnings [Member]	Confidentially Marketed Public Offering [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2023																																																								18,625	42,329,864
Balance at Dec. 31, 2023																																																								$ 18,625	$ 42	$ 129,763	$ (150,741)	$ (2,311)
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan (in shares)																																																								0	3,333			3,333
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan																																																								$ 0	$ 0	4	0	$ 4
Stock-based compensation	$ 0	$ 0	$ 4,183	$ 0	$ 4,183	$ 0	$ 0	$ 351	$ 0	$ 351
Vest - restricted stock awards (in shares)																																																								0	26,912
Vest - restricted stock awards																																																								$ 0	$ 0	0	0	0
Conversions - Senior Secured Convertible Note (in shares)											0	13,866,867
Conversions - Senior Secured Convertible Note											$ 0	$ 14	$ 13,468	$ 0	$ 13,482
Purchase - Employee Stock Purchase Plan (in shares)																																																								0	647,940
Purchase - Employee Stock Purchase Plan																																																								$ 0	$ 1	446	0	447
Stock issuance (in shares)																5,670	0				24,129	0														0	3,331,771
Stock issuance																$ 5,670	$ 0	$ 0	$ 0	$ 5,670	$ 24,129	$ 0	$ 0	$ 0	$ 24,129											$ 0	$ 3	$ 4,672	$ 0	$ 4,675
Exchange - Series A and Series A-1 Preferred Stock (in shares)																										(24,295)	0				(1,500)
Exchange - Series A and Series A-1 Preferred Stock																										$ (24,295)	$ 0	$ 0	$ (7,496)	$ (31,791)	$ 1,500
Issuance through exchange - Series B and Series B-1 Preferred Stock (in shares)																										31,790	0
Fair Value - 31,790 shares of Series B Preferred Stock issued in exchange for Series A and Series A-1 Preferred Stock																										$ 31,790	$ 0	0	0	31,790
Conversions - Series B Preferred Stock																										$ 24,295	$ 0	$ 0	$ 7,496	$ 31,791	$ (1,500)
Conversions - Series B Preferred Stock (in shares)																																2,075,263
Conversions - Series B Preferred Stock																																$ 2	$ 1,498	$ 0	$ 0
Issue common stock - vendor service agreement (in shares)																																																								0	790,000
Issue common stock - vendor service agreement																																																								$ 0	$ 1	640	0	641
Transfer of intellectual property from PAVmed Inc.																																																								0	0	(350)	0	(350)
Net loss																																																								$ 0	$ 0	0	(45,529)	(45,529)
Balance (in shares) at Dec. 31, 2024																																																								54,419	63,071,950
Balance at Dec. 31, 2024																																																								$ 54,419	$ 63	154,675	(203,766)	$ 5,391
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan (in shares)																																																								0	14,530			14,530
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan																																																								$ 0	$ 0	17	0	$ 17
Stock-based compensation	$ 0	$ 0	$ 4,387	$ 0	$ 4,387	$ 0	$ 0	$ 104	$ 0	$ 104
Purchase - Employee Stock Purchase Plan (in shares)																																																								0	355,459
Purchase - Employee Stock Purchase Plan																																																								$ 0	$ 0	272	0	$ 272
Stock issuance (in shares)																																									0	215,421			215,421	0	13,939,330				0	43,125,000
Stock issuance																																									$ 0	$ 0	$ 274	$ 0	$ 274	$ 0	$ 14	$ 14,921	$ 0	$ 14,935	$ 0	$ 43	$ 43,128	$ 0	$ 43,171
Exchange - Series A and Series A-1 Preferred Stock (in shares)																															(145)
Exchange - Series A and Series A-1 Preferred Stock																															$ 145
Conversions - Series B Preferred Stock																															$ (145)
Conversions - Series B Preferred Stock (in shares)																																116,523
Conversions - Series B Preferred Stock																																$ 0	$ 145	$ 0	$ 0
Issue common stock - vendor service agreement (in shares)																																																								0	112,500			112,500
Issue common stock - vendor service agreement																																																								$ 0	$ 0	138	0	$ 138
Net loss																																																								$ 0	$ 0	0	(58,010)	(58,010)
Issuance - Interest payment paid in stock (in shares)																																																								0	226,626
Issuance - Interest payment paid in stock																																																								$ 0	$ 1	256	0	257
Issuance - Dividend on Series B and Series B-1 Preferred Stock (in shares)																																																								0	9,921,423
Issuance - Dividend on Series B and Series B-1 Preferred Stock																																																								$ 0	$ 10	12,549		0
Issuance - Dividend on Series B and Series B-1 Preferred Stock																																																											(12,559)
Balance (in shares) at Dec. 31, 2025																																																								54,274	131,098,762
Balance at Dec. 31, 2025																																																								$ 54,274	$ 131	$ 230,866	$ (274,335)	$ 10,936

Lucid Diagnostics Inc. 10-K